242 related articles for article (PubMed ID: 31365177)
1. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S; Amaddeo G; Manini MA; López MF; Anders M; Pinter M; Rodríguez MJB; Cristóbal MR; Soteras GA; Piñero F; Villadsen GE; Weinmann A; Crespo G; Mazzaferro V; Regnault H; Giorgio M; González-Diéguez ML; Donato MF; Varela M; Wörns MA; Bruix J; Lampertico P; Reig M
Am J Transplant; 2019 Nov; 19(11):3176-3184. PubMed ID: 31365177
[TBL] [Abstract][Full Text] [Related]
2. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.
Iavarone M; Invernizzi F; Ivanics T; Mazza S; Zavaglia C; Sanduzzi-Zamparelli M; Fraile-López M; Czauderna C; Di Costanzo G; Bhoori S; Pinter M; Manini MA; Amaddeo G; Yunquera AF; Piñero F; Blanco Rodríguez MJ; Anders M; Aballay Soteras G; Villadsen GE; Yoon PD; Cesarini L; Díaz-González Á; González-Diéguez ML; Tortora R; Weinmann A; Mazzaferro V; Romero Cristóbal M; Crespo G; Regnault H; De Giorgio M; Varela M; Prince R; Scudeller L; Donato MF; Wörns MA; Bruix J; Sapisochin G; Lampertico P; Reig M
Liver Transpl; 2021 Dec; 27(12):1767-1778. PubMed ID: 34388851
[TBL] [Abstract][Full Text] [Related]
4. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
8. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn RS; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Gerolami R; Caparello C; Cabrera R; Chang C; Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J
J Hepatol; 2018 Aug; 69(2):353-358. PubMed ID: 29704513
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Pfeiffenberger J; Koschny R; Hoffmann K; Mehrabi A; Schmitz A; Radeleff B; Stremmel W; Schemmer P; Ganten TM
Langenbecks Arch Surg; 2013 Dec; 398(8):1123-8. PubMed ID: 24091908
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
[TBL] [Abstract][Full Text] [Related]
16. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Maeda T; Yokoyama M; Wakamatsu T; Inoue M; Saito T; Kobayashi K; Kiyono S; Nakamura M; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N
Invest New Drugs; 2018 Apr; 36(2):332-339. PubMed ID: 28891038
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
20. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
